JAK3 and non-small cell lung carcinoma: Another study showed that IL7R promoted the sensitivity of non-small cell lung cancer (NSCLC) cells by activating the IL-7R-JAK3/STAT5 signaling pathway to cisplatin, and inhibited tumor growth[27].